Supernus, Indivior merge to strengthen neuroscience drug portfolio

• The combined company will have 11 marketed medicines for conditions including opioid addiction, epilepsy, migraine, Parkinson's disease and attention-deficit hyperactivity disorder. The companies expect about $125 million in annual cost savings.
• Supernus shareholders will receive 1.5401 Indivior shares for each share held. Indivior shareholders will own about 56.5% of the combined company, while Supernus shareholders will hold the rest.
• Indivior shareholders will also receive a $1 billion special cash dividend immediately before the merger closes. The companies plan to fund $650 million of the dividend with new debt and the rest with existing cash.
• The combined company will be named Supernus, Inc and led by Supernus CEO Jack Khattar, the companies said. Together they are expected to have about $878 million in net debt.
• The company will have an eight-member board that will include four directors from each company.
• The merger is expected to close in the fourth quarter of 2026, subject to shareholder and regulatory approvals and other closing conditions.

Supernus Pharmaceuticals and Indivior Pharmaceuticals said on Monday they had agreed to an all-stock merger that would create a company with about in annual revenue and a portfolio of medicines for neurological, psychiatric and addiction-related conditions.